Academic Study Confounds Latest UK Zytiga Reimbursement Consultation
Janssen, the Institute of Cancer Research and patient groups have reacted with disappointment to NICE draft guidance recommending that Zytiga should not be funded by England's National Health Service in a subset of prostate cancer patients. But the existence of an academic study has complicated the situation in an unusual way, and Janssen still hopes to steer a path to reimbursement.
You may also be interested in...
Janssen and UK health technology assessment body NICE are being urged to sit down together and agree a suitable price for using Zytiga as a first-line treatment for advanced prostate cancer.
NICE, the health technology appraisal institute for England and Wales, has at last recommended the use of Janssen's Zytiga (abiraterone) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) before chemotherapy, three months after initially rejecting its use on the publicly funded National Health Service, due to inadequate cost-effectiveness and efficacy data.
A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.